This cluster is too small to warrant a trading response. Monitor for any C-suite selling or a cluster exceeding 0.5% of market cap, which would carry more signal. The broader 30-day insider selling trend ($13.2M) is worth watching, but this specific filing is noise.
DYN drugs
DYN drug pipeline →- ▲ z-rostudirsen 8/10 Filed (BLA under FDA Priority Review); Phase 3 confirmatory trial (FORZETTO) ongoing · PDUFA date Jan 21, 2027
- ◆ z-basivarsen 7/10 Phase 3 (HARMONIA confirmatory trial, initiated March 2026); Phase 1/2 registrational cohort (ACHIEVE) fully enrolled · BLA filing Q3 2027
- ● DYNE-302 2/10
- All DYN drugs, catalysts & trials →
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 23 $18.90entry
- T+1 · 7mo ago −3.39%α −4.16% · $18.26
- T+5 · 7mo ago −7.14%α −8.58% · $17.55
- T+20 · 6mo ago −8.10%α −12.93% · $17.37
- T+60 · 4mo ago +26.08%α +20.46% · $23.83
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Two Dyne Therapeutics directors, Jason Rhodes and Dirk Kersten, sold a combined $423K in open-market stock over a 2-day window (April 22-23, 2026). The sales represent approximately 0.014% of the company's $3.0B market cap, a trivial amount with no material economic signal. This follows a larger cluster of director sales totaling $4.97M over the prior week, but the current cluster is too small to indicate a change in outlook.
Key Financial Metrics
Key Facts
- Two directors sold a combined $423K in open-market transactions
- Sales represent ~0.014% of DYN's $3.0B market cap
- Director Jason Rhodes sold $370K; Director Dirk Kersten sold $53K
- All transactions were open-market sales (code S)
- No C-suite executives traded in this cluster
Financial Impact
Total insider sales of $423K, or 0.014% of market cap, economically negligible
Risk Factors
- Insider selling trend could accelerate if upcoming clinical data disappoints
- Director selling may precede negative news, though current amounts are trivial
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-DYN-1777328162648 |
Track record
54 reports on DYN
12 of 16 bullish or bearish reports moved the stock their way by T+20. Best: +46.36% at T+60 after the May 20, 2026 report. 15 of 16 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $16.77 Now $16.70 −0.39% settles Dec 15
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $17.16 Now $16.70 −2.68% settles Dec 15
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $17.16 Now $16.70 −2.68% settles Dec 15
- Nov 5, 202611d ago 8-K Neutral 5/10 No price data
- Nov 5, 202611d ago Press Release Neutral 5/10 Entry $17.36 Now $16.70 −3.80% settles Dec 4
- Oct 29, 202618d ago Institutional Cluster Neutral 2/10 Entry $17.04 Now $16.70 −2.00% settles Nov 27
- Oct 22, 202625d ago Press Release Neutral 2/10 Entry $15.62 Now $16.70 +6.91% settles Nov 20
- Oct 12, 20265w ago Institutional Cluster Mixed 4/10 Entry $15.96 to $18.62 Now $16.70 +4.64% ▲ +16.67% +19.93% vs SPY
- Sep 29, 20266w ago Press Release Bullish 7/10 Entry $16.11 to $16.94 Now $16.70 +3.66% ▲ +5.15% +4.23% vs SPY
- Sep 8, 20269w ago Insider Cluster Neutral 3/10 Entry $19.19 to $15.97 Now $16.70 −12.98% ▼ −16.78% −18.72% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers